All In Biotech

Drug Trial Radar · NCT05352178

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

a New Spark in Treating Oligorecurrent Prostate Cancer: Adding Systemic Treatment to Stereotactic Body Radiotherapy or Metastasectomy: Key to Long-lasting Event-free Survival?

Last checked: Nov 19, 2026Latest source record: Jul 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 873 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

873

Planned (sponsor's estimate)

Start

Apr 20, 2022

Primary completion

Apr 25, 2027

Study completion Apr 25, 2032

Sponsor

Lead sponsor
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed therapy (MDT) significantly prolongs poly-metastatic free survival (PMFS) and/or metastatic castration-refractory prostate cancer free survival (mCRPC-FS) in patients with oligorecurrent hormone sensitive prostate cancer.

Conditions

  • Prostate Cancer
  • Prostate Cancer Recurrent
  • Prostate Cancer Metastatic
  • Metastatic Cancer
  • Oligometastatic Disease
  • Oligometastasis
  • Hormone Sensitive Prostate Cancer

Interventions

  • Radiotherapy (SBRT) and/or surgery (metastasectomy)Other

    Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions

  • Androgen deprivation therapyDrug

    Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im

  • Androgen receptor targeted therapyDrug

    Enzalutamide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Poly-metastatic free survival (PMFS)Time frame: up to 5 years after MDT

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospitals Leuven

    Leuven, Belgium · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.